LVMUY-OTC 0 ACN-N -0.03 UNH-N -4.18 VALT-T 0.31 MART-T -0.14 VIDY-T 0.23 RPRX-Q 0.06
Atrium Innovations. (ATB-T)

Atrium Innovations. (ATB-T)

10 watching

0.00
0.00 (0.00%) 1d
0

Related posts

Nervous markets await Nvidia
SELL

Atrium Innovations.(ATB-T)

Dec 24, 2013

(Market Call Minute) Tender your shares. Gov’t may be reluctant to see this one go.

Jason DonvilleJason Donville
Unknown
Unlock Rating
$24.270

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Atrium Innovations.(ATB-T)

Nov 22, 2013

(A Top Pick Nov 28/12. Up 9.9%.) 5.75% bond maturing August 31/18.

Joey MackJoey Mack
No
Unlock Rating
$18.690

Stock price when the opinion was issued

Consumer Products
HOLD

Atrium Innovations.(ATB-T)

Apr 10, 2013

(Market Call Minute.) The negative on this is that they are big in Europe and the positive is that there is lots of consolidation in the industry.

Norman LevineNorman Levine
No
Unlock Rating
$12.400

Stock price when the opinion was issued

Consumer Products
TOP PICK

Atrium Innovations.(ATB-T)

Nov 28, 2012

5.75% bond maturing August 31/18. This is a convertible debenture. Company has fantastic interest coverage and very low debt.

Joey MackJoey Mack
No
Unlock Rating
$11.270

Stock price when the opinion was issued

Consumer Products
SELL

Atrium Innovations.(ATB-T)

Sep 24, 2012

Vitamin Business. Likes long term demographics of vitamin and supplement business. Unfortunately a lot of business is in Europe and is hurting them. Thinks there is definitely better places to be. He sold his holdings.

Norman LevineNorman Levine
No
Unlock Rating
$10.720

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Atrium Innovations.(ATB-T)

Jul 27, 2011
(A Top Pick Aug 11/10. Down 7.38%.) Largest US manufacturer and one of the largest in Europe of high quality vitamins and other supplements. Also made acquisitions that have got them into the health store business. This is a buying opportunity.
Norman LevineNorman Levine
Owned
Unlock Rating
$15.040

Stock price when the opinion was issued

Consumer Products
DON'T BUY

Atrium Innovations.(ATB-T)

Mar 15, 2011
If he bought it a month ago he would expect to sell it 5 years from now. Not really cheap. Would not buy it today and sell in 30 days. Would look at averaging the price.
Don ReedDon Reed
Unknown
Unlock Rating
$15.330

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Atrium Innovations.(ATB-T)

Dec 29, 2010
(A Top Pick Dec 23/09. Down 0.46%.) Canadian Based multinational consumer products company in the high quality vitamin supplements sold mostly though practitioners. Had to change a German product from a health supplement into a food additive, which has held back the sales. New product is selling well. Very low multiple. Good risk/reward. Still a Buy.
Norman LevineNorman Levine
Owned
Unlock Rating
$15.220

Stock price when the opinion was issued

Consumer Products
SELL

Atrium Innovations.(ATB-T)

Dec 06, 2010
In the nutri-ceuticals environment with drugs, health foods, etc. Hard to read how the market place is playing out in this sector. Prefers Paladin Labs (PLB-T) and would into this one instead.
Jason DonvilleJason Donville
No
Unlock Rating
$14.390

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Atrium Innovations.(ATB-T)

Nov 09, 2010
(Top Pick Nov 16/09, Down 2%) Nutrition business. Biggest maker of high quality supplements sold through practitioners. A German product changed classification from drug to food additive. They grow through acquisition and he expects them to do that next year.
Norman LevineNorman Levine
Owned
Unlock Rating
$15.330

Stock price when the opinion was issued

Consumer Products
TOP PICK

Atrium Innovations.(ATB-T)

Sep 15, 2010
(A Top Pick Aug 19/09. Up 2.3%.) Premium nutritional products manufacturer. Trading around 8X earnings. Well managed. Had a couple of tough quarters with the weakness in the euro but that has turned around. Hoping to have 20% of the US market. Organic and acquisition growth.
Ara NalbandianAra Nalbandian
Owned
Unlock Rating
$14.070

Stock price when the opinion was issued

Consumer Products
BUY

Atrium Innovations.(ATB-T)

Sep 07, 2010
Natural products. Earnings 3 weeks ago were basically in line. Most of street were happy. One analyst lowered to a hold and there was a sell-off. He likes the outlook for ATB. Near term it has stalled out and given investors an opportunity here.
Norman LevineNorman Levine
Owned
Unlock Rating
$14.170

Stock price when the opinion was issued

Consumer Products
TOP PICK

Atrium Innovations.(ATB-T)

Aug 11, 2010
Canadian-based multinational consumer company and largest player in high quality vitamins/supplements sold through practitioners. Market is growing 6%-7%. About half their business is out of Europe. Growth through acquisitions. Severely undervalued. Longer term play.
Norman LevineNorman Levine
Owned
Unlock Rating
$16.250

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Atrium Innovations.(ATB-T)

Jun 23, 2010
(A Top Pick May 15/09. Up %.) (Think this should be Aug 19 and up 12.54%, not May 15 as BNN shows. Bill) Still likes this one.
Ara NalbandianAra Nalbandian
Owned
Unlock Rating
$15.450

Stock price when the opinion was issued

Consumer Products
PAST TOP PICK

Atrium Innovations.(ATB-T)

Jun 09, 2010
(Top Pick Jun 23/09, Up 13.55) But he sold out early and at a loss. Wouldn’t buy now. It’s making new lows.
Jeff Parent B. Eng. FCSI CIMJeff Parent B. Eng. FCSI CIM
No
Unlock Rating
$14.210

Stock price when the opinion was issued

Consumer Products
Showing 1 to 15 of 58 entries
Next PageNext Page

Atrium Innovations.(ATB-T) Rating

Ranking : 1 out of 5

Star iconStar empty iconStar empty iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Atrium Innovations. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Atrium Innovations.(ATB-T) Frequently Asked Questions

What is Atrium Innovations. stock symbol?

Atrium Innovations. is a OTC stock, trading under the symbol ATB-T on the (). It is usually referred to as or ATB-T

Is Atrium Innovations. a buy or a sell?

In the last year, there was no coverage of Atrium Innovations. published on Stockchase.

Is Atrium Innovations. a good investment or a top pick?

Atrium Innovations. was recommended as a Top Pick by on . Read the latest stock experts ratings for Atrium Innovations..

Why is Atrium Innovations. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Atrium Innovations. worth watching?

0 stock analysts on Stockchase covered Atrium Innovations. In the last year. It is a trending stock that is worth watching.

What is Atrium Innovations. stock price?

On , Atrium Innovations. (ATB-T) stock closed at a price of $.

Build our watch list

Sign in to track investments
you care about

Latest Buy Signals

CMG-N -1.46$49.99
CP-T -0.25$102.39
ATZ-T -0.39$59
AZN-N 0.65$67.95
SBUX-Q -1.31$80.88

Today's Top Picks

LVMUY-… 0$109.799
ACN-N -0.03$308.85
UNH-N -4.18$381.37
VALT-T 0.31$40.91
MART-T -0.14$22.76

Popular Articles

Latest Sell Signals

NVDA-Q -0.655$116.715
MCD-N -1.14$312.35
HPYT-T 0.01$9.19
RHT-X 0.005$0.215
GOOG-Q -1.435$154.315

Most Recent Experts

Michael Hakes - CFA, MBA

Michael Hakes - CFA, MBA

Murray Wealth Group

Daniel Straus

Daniel Straus

National Bank Financial

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: hello@stockchase.com.

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© Stockchase Inc. by Wealthica